🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Advanced Hepatocellular Carcinoma (HCC)

Regional Lymph Node Metastasis and Survival Outcomes in Advanced HCC NCT06876753n/a2 sites📍 Nanjing📍 Nanjing Zhongda Hospital FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma NCT07012798Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: Durvalumab, Bevacizumab, HAIC of FOLFOX Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma NCT07832006Phase 21 site📍 Beijing Shunda Du · Tests: Irreversible Electroporation, Lenvatinib, Sintilimab Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC NCT07500220Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: EB-G3B7-NK dual-target CAR-NK cells, Fludarabine, Cyclophosphamide A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors NCT05208762Phase 162 sites📍 Birmingham📍 Birmingham📍 Birmingham Seagen, a wholly owned subsidiary of Pfizer · Tests: PF-08046054, pembrolizumab Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer NCT07174570Phase 24 sites📍 Atlanta📍 Atlanta📍 Atlanta Emory University · Tests: Celecoxib, Durvalumab, Tremelimumab, Biospecimen Collection, Computed Tomography Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies NCT04282044Phase 13 sites📍 Scottsdale📍 La Jolla📍 Stanford BioEclipse Therapeutics · Tests: CRX100 suspension for infusion, Fludarabine, Cyclophosphamide Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC NCT05608200Phase 31 site📍 Guangzhou Second Affiliated Hospital of Guangzhou Medical University · Tests: Lenvatinib, sintilimab plus TACE, Lenvatinib plus TACE Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant NCT06725121Phase 1, Phase 22 sites📍 London📍 Toronto University Health Network, Toronto · Tests: Atezolizumab & Bevacizumab, Yttrium-90 (Y-90), Stereotactic body radiotherapy (SBRT) PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver Cancer NCT07884877Phase 21 site📍 Seoul Samsung Medical Center · Tests: PULSAR (Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy), Immune checkpoint inhibitor-based therapy Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment NCT07147101n/a1 site📍 Shanghai Fudan University · Tests: Sintilimab, Bevacizumab Biosimilar, Camrelizumab, Rivoceranib, Nivolumab Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors NCT06938880Phase 1, Phase 21 site📍 Guangzhou Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Tests: ZGGS18 for Injection, ZG005 for Injection Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study NCT07405086Phase 41 site📍 Portland OHSU Knight Cancer Institute · Tests: Biospecimen Collection, Immune Checkpoint Inhibitor PIN in Combination With Anti-PD1 in Previously Treated Primary Hepatocellular Carcinoma NCT07018518Phase 11 site📍 Beijing Chinese PLA General Hospital · Tests: PIN +anti-PD1 Study of AU409 Capsule in Advanced Hepatocellular Carcinoma Patients Who Failed Standard Treatment NCT06374485Phase 11 site📍 Hong Kong Lee's Pharmaceutical Limited · Tests: AU409 Ligufalimab and Cadonilimab in Advanced Liver Cancers NCT06789848Phase 21 site📍 Dallas University of Texas Southwestern Medical Center · Tests: Ligufalimab, Cadonilimab Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor NCT03093688Phase 1, Phase 21 site📍 Shanghai Shanghai Public Health Clinical Center · Tests: Infusion of iNKT cells and CD8+T cells A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors NCT07749586Phase 1, Phase 24 sites📍 New York📍 Huntersville📍 San Antonio Arvinas Inc. · Tests: ARV-6723, Pembrolizumab, SOC Defining the Ablative Dose for Y-90 TARE NCT07586046Phase 21 site📍 Chicago Northwestern University · Tests: Yttrium-90 Radiation Segmentectomy (Y90 RS) using glass microspheres Atezolizumab and BEvacizumab With STereotactic Body Radiotherapy for Advanced Hepatocellular Carcinoma NCT06595108NA1 site📍 Yongin-si Yonsei University · Tests: Stereotactic body radiotherapy STRATHEP: AI-Driven Treatment Stratification for Advanced Hepatocellular Carcinoma NCT07863258n/a5 sites📍 Anderlecht📍 Bonheiden📍 Bruges Universitaire Ziekenhuizen KU Leuven Anti-PD-1/PD-L1 Antibodies Plus Anti-VEGF Antibody Treatment in Patients With Advanced-Stage HCC NCT06537908n/a1 site📍 Shanghai Shanghai Zhongshan Hospital · Tests: Anti-PD-1/PD-L1 antibodies, Anti-VEGF A Phase I Study of CREPT-618 in Locally Advanced HCC NCT07364357Phase 11 site📍 Beijing Cancer Institute and Hospital, Chinese Academy of Medical S… · Tests: gene therapy JMT106 Injection in the Treatment of Advanced Solid Tumors NCT07275073Phase 11 site📍 Zhejiang Shanghai JMT-Bio Inc. · Tests: JMT106 Injection SBRT in HCC With Oligoprogression on First-line Immunotherapy NCT06434480NA1 site📍 Hong Kong Chinese University of Hong Kong · Tests: Stereotactic Body Radiation Therapy (SBRT) Combination of TATE and PD-1 Inhibitor in Liver Cancer NCT03259867Phase 23 sites📍 Orange📍 Oklahoma City📍 Milwaukee Teclison Ltd. · Tests: Nivolumab Injectable Product, Trans-arterial tirapazamine embolization A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) NCT07430202Phase 11 site📍 Baltimore Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Tests: DNAJB1-PRKACA Peptide Vaccine, DRP-104, Nivolumab, Ipilimumab Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer NCT05323201Phase 1, Phase 21 site📍 Xuzhou The Affiliated Hospital of Xuzhou Medical University · Tests: fhB7H3.CAR-Ts, Fludarabine, Cyclophosphamide Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma NCT06254248Phase 210 sites📍 Clichy📍 Créteil📍 Lille Assistance Publique - Hôpitaux de Paris · Tests: Systemic therapy Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma NCT04430452Phase 21 site📍 San Francisco Mary Feng, MD · Tests: Durvalumab, Hypofractionated Radiation Therapy, Tremelimumab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy